Trends in estrogen administration routes and associations with selected cardiometabolic conditions among US women aged 40 years and older: MEPS, 2017–2023
Background Estrogen administration routes are clinically relevant in women with cardiometabolic diseases (CMDs). We examined associations between CMDs and recorded estrogen administration route. Methods We analyzed women aged ≥40 years with oral or transdermal estrogen use in the 2017–2023 Medical Expenditure Panel Survey. CMDs comprised hypertension, diabetes, and hypercholesterolemia. Survey-weighted logistic models adjusted for age, year, race/ethnicity, insurance, income, education, region, and marital status. Annual route distributions were also evaluated. Results The sample included 1,148 person-years from 724 women. Transdermal use accounted for 29.3% overall and 32.8%, 31.6%, and 21.1% among observations with zero, one, and at least two CMDs, respectively. Adjusted odds ratios were 0.95 (95% CI, 0.62–1.45) for any CMD and 0.77 (95% CI, 0.44–1.34) for at least two CMDs compared with none. Annual transdermal use increased from 19.7% in 2017 to 38.3% in 2023; the adjusted odds ratio per year was 1.14 (95% CI, 1.05–1.25). Conclusion Transdermal estrogen represented an increasing share of use. Adjusted associations with CMDs were imprecise. Further research should examine how disease control and patient preferences relate to route selection.
Authors
- Xingchen Liu (ORCID: https://orcid.org/0000-0002-5638-4053)
- Yu-Jun Xiong
- Yan Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Hospital (CN)
- Jinan Stomatological Hospital (CN)
- Xinyang Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fphar.2026.2015564
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00